brianletort.ai
← Library

2IQP multicenter trial / Tandem Diabetes Care

Verified evidenceAutonomous + backstopContinuous decisioning

CGM-driven automated insulin delivery

Bounded closed-loop control can adjust insulin while patients and clinicians retain targets and safety response.

Clinical operations · United States and Canada

Collections: Regulated autonomy

An editorial scene for 2IQP multicenter trial / Tandem Diabetes Care contrasts uses the pretrial insulin-delivery method and continuous glucose information to manage insulin. with uses cgm data to modulate insulin delivery between patient interactions. in the cgm-driven automated insulin delivery workflow.

Executive brief

The operating-model shift, in one view.

Automating a frequent decision can improve outcomes when authority boundaries and safety fallback are explicit.

AI value · HbA1c

Verified

7.3% AID vs 7.7% control at week 13; adjusted difference −0.6 percentage points

Open device intervention funded by Tandem; one severe hypoglycemia event occurred in the AID group.

Before

Uses the pretrial insulin-delivery method and continuous glucose information to manage insulin. → Adjust therapy using ordinary care and respond to high/low glucose.

After

Uses CGM data to modulate insulin delivery between patient interactions. → Manage meals, device operation, supplies, alarms, and clinical review.

Human boundary

The algorithm controls bounded dose delivery; patients and clinicians retain therapy selection, targets, and safety response.

Why it matters

Bounded closed-loop control can adjust insulin while patients and clinicians retain targets and safety response.

How the work changed

Before

How the work ran before the change.

  1. Step 1 of 2

    Patient

    Uses the pretrial insulin-delivery method and continuous glucose information to manage insulin.

    ControlControl participants continued pretrial delivery and received CGM; the article does not impose one manual dosing sequence.

  2. Step 2 of 2

    Patient and diabetes clinician

    Adjust therapy using ordinary care and respond to high/low glucose.

    ControlClinical oversight and hypoglycemia safety plan.

What changed

Bounded closed-loop control can adjust insulin while patients and clinicians retain targets and safety response.

Decision rightAI acts within a human backstop

After

How the same work runs now.

  1. Step 1 of 2

    Automated insulin-delivery algorithm

    Uses CGM data to modulate insulin delivery between patient interactions.

    ControlConfigured glucose targets, pump limits, CGM availability, and safety alarms.

  2. Step 2 of 2

    Patient and clinician

    Manage meals, device operation, supplies, alarms, and clinical review.

    ControlHumans retain treatment enrollment and emergency response; severe events follow trial safety procedures.

Process model built from the published workflow evidence for 2IQP multicenter trial / Tandem Diabetes Care. Every step, actor, and control appears in full below.
Every step, actor, and control

Exception path

Sensor/pump failure, alarms, hypoglycemia, or unsuitable conditions revert to manual safety procedures.

Work removed

  • Repeated routine dose calculations between clinical reviews

Decision authority

The algorithm controls bounded dose delivery; patients and clinicians retain therapy selection, targets, and safety response.

Before

  1. 01

    Patient

    Uses the pretrial insulin-delivery method and continuous glucose information to manage insulin.

    Control: Control participants continued pretrial delivery and received CGM; the article does not impose one manual dosing sequence.

  2. 02

    Patient and diabetes clinician

    Adjust therapy using ordinary care and respond to high/low glucose.

    Control: Clinical oversight and hypoglycemia safety plan.

After

  1. 01

    Automated insulin-delivery algorithm

    Uses CGM data to modulate insulin delivery between patient interactions.

    Control: Configured glucose targets, pump limits, CGM availability, and safety alarms.

  2. 02

    Patient and clinician

    Manage meals, device operation, supplies, alarms, and clinical review.

    Control: Humans retain treatment enrollment and emergency response; severe events follow trial safety procedures.

Work that left the path

  • Repeated routine dose calculations between clinical reviews

Human role before

Patients and clinicians calculate or adjust insulin through their existing delivery method.

Human role after

Patients oversee the device and clinicians manage therapy while the algorithm adjusts routine delivery.

AI roleClosed-loop modulation of insulin from CGM data.

Outcomes

HbA1c

Verified

8.2% AID and 8.1% control7.3% AID vs 7.7% control at week 13; adjusted difference −0.6 percentage points

13 weeks · 319 randomized adults with insulin-treated type 2 diabetes

Open device intervention funded by Tandem; one severe hypoglycemia event occurred in the AID group.

What leaders can reuse

Anti-pattern

Do not infer that autonomous dosing removes patient workload or severe-event risk.

Questions

  1. 01Where is the operating threshold set and who can override it?
  2. 02What measured result would trigger rollback or retraining?
  3. 03Which residual decisions must remain human-owned?

Portability conditions

  • Validated device
  • Reliable sensor and pump
  • Patient training
  • Clinical oversight

Reputation risk

high

Evidence and authority

What the public record supports.

Current · updated

1 independent, 1 peer reviewed; publication outcomes are verified.

Bundle 1.0.0 · reviewed 2026-08-23 · stable ID 13efd27ef861d7ae

Related transformations

More in Clinical operations

Sources

Read the evidence, freshness, caveat, and version policy.